Effect of Bacopa Monnieri on Working Memory and Cognitive Processing in Student

NCT ID: NCT02931747

Last Updated: 2017-08-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-07-31

Study Completion Date

2017-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the effect of Bacopa Monnieri on working memory and cognitive processing in student.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Learning and working memory are two of the key role for studying and work successful for student particular the high school student who study hard and preparing themselves for the graduate study. The consumption of brain booster product or functional food for improving memory has gained much attention. It has been reported that Bacopa Monnieri could improve learning and working memory in elderly subject by improving the N100 and P300 event related potential. Therefore, Bacopa Monnieri might be the potential product for improving the learning and working memory in student particular high school student.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Subjects are received the pill of placebo which has same color, shape and smell like the Bacopa Monnieri once daily for 16 weeks.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Subjects are received Placebo once daily for 16 weeks.

Bacopa Monnieri 300 mg/day

Subjects are received the pill of Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks

Group Type ACTIVE_COMPARATOR

Bacopa Monnieri 300 mg/day

Intervention Type DIETARY_SUPPLEMENT

Subjects are received Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks.

Bacopa Monnieri 600 mg/day

Subjects are received the pill of Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks

Group Type ACTIVE_COMPARATOR

Bacopa Monnieri 600 mg/day

Intervention Type DIETARY_SUPPLEMENT

Subjects are received Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

Subjects are received Placebo once daily for 16 weeks.

Intervention Type DIETARY_SUPPLEMENT

Bacopa Monnieri 300 mg/day

Subjects are received Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks.

Intervention Type DIETARY_SUPPLEMENT

Bacopa Monnieri 600 mg/day

Subjects are received Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy student subject aged between 15-18 years old who studying in the school within Khon Kaen province.
* Body mass index is between 18.5-24.9

Exclusion Criteria

* Subjects who are diagnosed with one of the following: cardiovascular diseases, respiratory disease, neuropsychological diseases, head injury, diabetes mellitus, liver disease, cancer, autoimmune disease and hematological disorder are excluded.
* Subjects who take any medicine or nutraceuticals or hormone that effect on central nervous system are excluded.
* Alcohol addict or smoking addiction (more than 10 pieces/day)
* Athlete or subjects who have a regular exercise more than 3 times/week
* Subjects who don't follow the instruction during the trial
* Subjects who are participating the other project.
Minimum Eligible Age

15 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Government Pharmaceutical Organization

UNKNOWN

Sponsor Role collaborator

Khon Kaen University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jintanaporn Wattanathorn

Associated Professor Doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Jitanaporn Wattanathorn

Khon Kaen, , Thailand

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Thailand

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HE581418

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Oral Bedtime Melatonin in Critically Ill Patients
NCT06156059 NOT_YET_RECRUITING PHASE4